Avanir Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Published: Jan, 2014 | Pages: 39 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Summary

Global Market Direct's pharmaceuticals report, "Avanir Pharmaceuticals, Inc. - Product Pipeline Review - 2014" provides data on the Avanir Pharmaceuticals, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Avanir Pharmaceuticals, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from Avanir Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Avanir Pharmaceuticals, Inc. - Brief Avanir Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Avanir Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Avanir Pharmaceuticals, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Avanir Pharmaceuticals, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Avanir Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Avanir Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Avanir Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Avanir Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Avanir Pharmaceuticals, Inc. and identify potential opportunities in those areas.

 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Avanir Pharmaceuticals, Inc. Snapshot 5
Avanir Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Avanir Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Avanir Pharmaceuticals, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Avanir Pharmaceuticals, Inc. - Pipeline Products Glance 14
Avanir Pharmaceuticals, Inc. - Late Stage Pipeline Products 14
Phase III Products/Combination Treatment Modalities 14
Avanir Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Avanir Pharmaceuticals, Inc. - Drug Profiles 17
(dextromethorphan hydrobromide + quinidine sulfate) 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
sumatriptan succinate 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
AVP-786 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Avanir Pharmaceuticals, Inc. - Pipeline Analysis 22
Avanir Pharmaceuticals, Inc. - Pipeline Products by Therapeutic Class 22
Avanir Pharmaceuticals, Inc. - Pipeline Products by Target 24
Avanir Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 25
Avanir Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 26
Avanir Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 27
Avanir Pharmaceuticals, Inc. - Recent Pipeline Updates 28
Avanir Pharmaceuticals, Inc. - Dormant Projects 32
Avanir Pharmaceuticals, Inc. - Discontinued Pipeline Products 33
Discontinued Pipeline Product Profiles 33
AVP-13358 33
AZD-2479 33
Avanir Pharmaceuticals, Inc. - Company Statement 34
Avanir Pharmaceuticals, Inc. - Locations And Subsidiaries 37
Head Office 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39

List of Tables
Avanir Pharmaceuticals, Inc., Key Information 5
Avanir Pharmaceuticals, Inc., Key Facts 5
Avanir Pharmaceuticals, Inc. - Pipeline by Indication, 2014 8
Avanir Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9
Avanir Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 10
Avanir Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2014 11
Avanir Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014 12
Avanir Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 13
Avanir Pharmaceuticals, Inc. - Phase III, 2014 14
Avanir Pharmaceuticals, Inc. - Phase II, 2014 15
Avanir Pharmaceuticals, Inc. - Phase I, 2014 16
Avanir Pharmaceuticals, Inc. - Pipeline by Therapeutic Class, 2014 23
Avanir Pharmaceuticals, Inc. - Pipeline by Target, 2014 24
Avanir Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 25
Avanir Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 26
Avanir Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 27
Avanir Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 28
Avanir Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 32
Avanir Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 33